Trifluridine/tipiracil plus bevacizumab (FTD/TPI plus BEV) and trifluridine/tipiracil (FTD/TPI) monotherapy in metastatic colorectal cancer (mCRC): Results of a meta-analysis.

被引：0
|
作者：
Yoshino, Takayuki
Taieb, Julien
Andre, Thierry
Kuboki, Yasutoshi
Pfeiffer, Per
Kumar, Amit
Hochster, Howard S.
机构：
[1] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Japan
[2] Paris Descartes Univ, Hop Europ een Georges Pompidou, Paris, France
[3] Hop St Antoine, Paris, France
[4] Natl Canc Ctr Hosp East, Kashiwa, Japan
[5] Odense Univ Hosp, Odense, Denmark
[6] SmartAnalyst India Pvt Ltd, Gurugram, Haryan, India
[7] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3568
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Safety run-in evaluation of the phase I trial of trifluridine/tipiracil (FTD/TPI) in combination with oxaliplatin and a monoclonal antibody (bevacizumab or nivolumab) in patients (pts) with metastatic colorectal cancer (mCRC)
    Calvo Ferrandiz, A.
    Dahan, L.
    Hollebecque, A.
    Prager, G.
    Andre, T.
    Argiles Martinez, G.
    Bordonaro, R.
    Stein, A.
    Tortora, G.
    Leger, C.
    Amellal, N.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [42] Efficacy and safety of trifluridine/tipiracil (FTD/TPI) in European patients with heavily pretreated metastatic gastric cancer (mGC): An analysis of the TAGS study
    Alsina, M.
    Tabernero, J.
    Arkenau, H-T.
    Squadroni, M.
    Doi, T.
    Faustino, C.
    Ghidini, M.
    Mansoor, W.
    Shitara, K.
    Van Cutsem, E.
    Causse-Amellal, N.
    Leger, C.
    Skanji, D.
    Ilson, D.
    ANNALS OF ONCOLOGY, 2019, 30
  • [43] Analysis of symptoms and functional HRQoL scales in TAGS, a phase III trial of trifluridine/tipiracil (FTD/TPI) in metastatic gastric cancer (mGC).
    Alsina, Maria
    Tabernero, Josep
    Shitara, Kohei
    Doi, Toshihiko
    Dvorkin, Mikhail
    Mansoor, Wasat
    Arkenau, Hendrik-Tobias
    Prokharau, Aliaksandr
    Ghidini, Michele
    Faustino, Catia
    Gorbunova, Vera
    Zhavrid, Edvard
    Nishikawa, Kazuhiro
    Ando, Takayuki
    Yalcin, Suayib
    Van Cutsem, Eric
    Skanji, Donia
    Leger, Catherine
    Sabater, Javier
    Ilson, David H.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [44] Pooled safety analysis from phase 3 studies of trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC) and metastatic colorectal cancer (mCRC).
    Van Cutsem, Eric
    Hochster, Howard S.
    Shitara, Kohei
    Mayer, Robert J.
    Ohtsu, Atsushi
    Falcone, Alfredo
    Yoshino, Takayuki
    Doi, Toshihiko
    Ilson, David H.
    Arkenau, Hendrik-Tobias
    George, Ben
    McGuigan, Sandra
    Makris, Lukas
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [45] Predictive marker for response to trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer patients
    Takahashi, Toshiaki
    Shigeyasu, Kunitoshi
    Kondo, Yoshitaka
    Takeda, Sho
    Umeda, Hibiki
    Moriwake, Kazuya
    Kayano, Masashi
    Sakurai, Yuya
    Nakamura, Shunsuke
    Takahashi, Masafumi
    Nitta, Kaori
    Yoshida, Kazuhiro
    Matsumi, Yuki
    Michiue, Hiroyuki
    Yamamoto, Hideki
    Kishimoto, Hiroyuki
    Teraishi, Fuminori
    Shoji, Ryohei
    Kanaya, Nobuhiko
    Kashima, Hajime
    Kakiuchi, Yoshihiko
    Kuroda, Shinji
    Kagawa, Shunsuke
    Fujiwara, Toshiyoshi
    BMC CANCER, 2025, 25 (01)
  • [46] The impact of prior therapies on outcomes with trifluridine/tipiracil (FTD/TPI) in the phase III TAGS trial.
    Shitara, Kohei
    George, Ben
    Taieb, Julien
    Sundar, Raghav
    Fakih, Marwan
    Makris, Lukas
    Benhadji, Karim A.
    Ghidini, Michele
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [47] Retrospective cohort study of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer: A real-world data from 4 hospitals in Portugal
    Menezes, M.
    Araujo, J.
    Fonseca, F.
    da Silva, D. Neto
    Trabulo, C.
    Dunoes, I.
    Baio, G.
    Bastos, I.
    Oliveira, A.
    Inacio, M.
    Dinis, R.
    ANNALS OF ONCOLOGY, 2023, 34 : S119 - S120
  • [48] Safety and efficacy of trifluridine/tipiracil plus bevacizumab in RAS mutated patients with metastatic colorectal cancer
    Michalaki, Vasiliki
    Theodosopoulos, Thedosios
    Vezakis, Antonios
    Papaconstantinou, Ioannis
    Kontis, Ioannis
    Dafnios, Nikolaos
    Frangoulidis, George
    Karandrea, Despina
    Papadimitriou, Christos
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [49] Phase I/II study of trifluridine/tipiracil plus XB2001 versus trifluridine/tipiracil in metastatic colorectal cancer
    Fumet, Jean-David
    Roussot, Nicolas
    Bertaut, Aurelie
    Limagne, Emeric
    Thibaudin, Marion
    Hervieu, Alice
    Zanetta, Sylvie
    Borg, Christophe
    Senellart, Helene
    Pernot, Simon
    Thuillier, Frederic
    Carnot, Aurelien
    Mineur, Laurent
    Chibaudel, Benoist
    Touchefeu, Yann
    Martin-Babau, Jerome
    Jary, Marine
    Labourey, Jean-Luc
    Rederstorff, Emilie
    Lepage, Come
    Ghiringhelli, Francois
    FUTURE ONCOLOGY, 2024, 20 (38) : 3077 - 3085
  • [50] Sequential treatment with regorafenib (REG) and trifluridine/tipiracil (TAS) plus /- bevacizumab (Bev) in refractory metastatic colorectal cancer (mCRC) in community clinical practice in the USA
    Bekaii-Saab, T.
    Ahn, D.
    Yuan, C.
    Jiao, X.
    Kurtinecz, M.
    Pan, X.
    Vassilev, Z.
    Ostojic, H.
    ANNALS OF ONCOLOGY, 2023, 34 : S442 - S442
12345